Protein Kinase C, epsilon, Recombinant, Human (PKCe)

Recombinant Human PKC-epsilon produced in Sf9 is a glycosylated, polypeptide chain containing amino acids 2-737 and having a molecular mass of 87kD. PKC-e is purified by proprietary chromatographic techniques. This protein is the full-length form of the protein with an amino terminal poly His-tag.\n\nUnit Definition: \n~3250 units/mg. One unit of PKC activity transfers 1 nmole of phosphate to a PKC substrate peptide per minute at 30 degrees C. Recombinant human active PKC also phosphorylates full length myelin basic protein, MARKS, GAP-34, and raf-1 kinase. Activity requires incubation with lipid activators, and may vary depending on the substrate and reaction conditions. The optimal concentration should be determined for each specific application.\n\nStorage: \nStore at 4 degrees C if entire vial will be used within 2-4 weeks. Store frozen at -20 degrees C for longer periods of time. Please avoid freeze-thaw cycles.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

P9103-20G1

Size

2ug

Form

Supplied as a liquid in 10mM Tris, pH 7.4, 0.1M sodium chloride, 20% glycerol, 1mM DTT, 0.1mM EDTA, 0.2mM PMSF and 0.03% Brij-35.

Purity

(same/more than) 90% (SDS-PAGE)

References

1. Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta.\n\nJ Med Chem 2006 May 4;49(9):2681-8\n\n2. Novel protein kinase C-epsilon inhibits human CYP11B2 gene expression through ERK1/2 signalling pathway and JunB.\n\nJ Mol Endocrinol 2006 Feb;36(1):51-64\n\n3. Divergent contractile and structural responses of the murine protein kinase C-epsilon null pulmonary circulation to chronic hypoxia.\n\nChest 2005 Dec;128(6 Suppl):620S-621S\n\n4. Targeting of protein kinase C-epsilon during Fcgamma receptor-dependent phagocytosis requires the epsilonC1B domain and phospholipase C-gamma1.\n\nMol Biol Cell 2006 Feb;17(2):799-813\n\n5. Angiotensin I-converting enzyme inhibitors block protein kinase C epsilon by activating bradykinin B1 receptors in human endothelial cells.\n\nJ Pharmacol Exp Ther 2006 Mar;316(3):1153-8\n\n6. Evidence that insulin-like growth factor-1 requires protein kinase C-epsilon, PI3-kinase and mitogen-activated protein kinase pathways to protect human vascular smooth muscle cells from apoptosis.\n\nImmunol Cell Biol 2005 Dec;83(6):651-67